Original Article
Small intestinal bacterial overgrowth and evaluation of intestinal barrier function in patients with ulcerative colitis

Chunchun Yang*, Xueyi Zhang*, Suming Wang, Xiaohui Huo, Jing Wang

Gastroenterology Department, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. *Equal contributors.

Received January 30, 2021; Accepted February 20, 2021; Epub June 15, 2021; Published June 30, 2021

Abstract: Objective: To investigate the small intestinal bacterial overgrowth (SIBO) and to evaluate the intestinal barrier function in ulcerative colitis (UC) patients treated with mesalazine and rifaximin. Methods: 96 patients undergoing the methane-hydrogen breath test in our hospital from January 2018 to January 2020 were enrolled in the study group, and 40 healthy persons were enrolled in the control group during this period. The SIBO positive rate of the two groups were collected and compared. Then, the SIBO positive patients were divided into group A and group B. Group A and group B all received mesalazine, and group B received rifaximin plus. The clinical efficacy, erythrocyte sedimentation rate (ESR), C reactive protein (CRP), and intestinal barrier function indexes like diamine oxidase (DAO) and D-lactic acid (DLA) were recorded and compared. Results: The study group presented higher SIBO positive rate compared with the control group (56% vs. 25%, P<0.05). After treatment, group B showed better clinical efficacy and lower levels of ESR and CRP than group A (all P<0.05). After treatment, the DAO and D-LA levels of the two groups were decreased, and presented lower levels in group B than group A (all P<0.05). Conclusion: UC patients present a higher positive rate in SIBO. Mesalazine and rifaximin are applied to patients with mild to moderate UC, and their clinical efficacy has been significantly enhanced after the eradication of SIBO.

Keywords: Ulcerative colitis, small intestinal bacterial overgrowth, intestinal barrier function

Introduction
Ulcerative colitis (UC), a non-specific ulcerative colitis, is a chronic inflammatory disease of the rectum and colon, for which, the pathogenesis hasn’t been elucidated [1]. UC is characterized by chronic inflammation and repeated attacks. Thus, UC is challenging to be cured completely, and it usually complies with clinical symptoms such as fever, bloody diarrhea, abdominal pain, weight loss, etc. As the significant factor to change inflammatory response and immune response, gut flora affects the development of UC. Chronic inflammatory response and immune response disorder are the crucial parts to induce UC [2, 3]. The incidence of ulcerative colitis has increased over the years due to the poor lifestyle and tremendous work pressure [4-6].

Small intestinal bacterial overgrowth (SIBO), defined as the increase in external bacteria and resident bacteria in the intestine, leads to food overfermentation, mucosal inflammation, small intestine permeability destruction, malabsorption, and villus damage. SIBO is closely associated with many other diseases such as non-alcoholic fatty liver, irritable bowel syndrome, deep vein thrombosis, diabetes, inflammatory bowel, etc. [7, 8]. The imbalance of intestinal symbiotic bacteria and pathogenic bacteria destroys the biological barrier of the intestinal mucosa and poses unavoidable damage to the mechanical and immune barrier [9, 10]. The intestinal barrier damage could lead to some conditional pathogenic bacteria in the intestine to translocate and enter the lamina propria to activate the mucosa-related immune system [11-13]. SIBO was detected by the breath test in this study at the advantages of simplicity, low cost, and non-invasiveness. This study aims to investigate SIBO and evaluate the intestinal barrier function in patients with ulcerative colitis.
Small intestinal bacterial overgrowth and evaluation of intestinal barrier

Materials and methods

General materials

96 patients undergoing the methane-hydrogen breath test in our hospital from January 2018 to January 2020 were enrolled in the study group, and 40 healthy persons were enrolled in the control group during this period. The study group consisted of 28 males and 22 females with a mean age of (42.9±4.3) years old. The control group consisted of 21 males and 19 females with a mean age of (41.7±4.4) years old. No statistical significance was observed in the general materials of the two groups (P > 0.05).

Inclusion and exclusion criteria

Inclusion criteria: 1) Diagnosed with UC [14]; 2) Not taking antibiotics, probiotics etc. recently; 3) With cognitive and communication skills; 4) Approved by the hospital ethics committee, and the written informed consent was provided by the participants.

Exclusion criteria: 1) With the history of colectomy; 2) With sever liver disease, acute infection, other chronic inflammatory diseases; 3) Pregnancy; 4) With diabetes. 5) With long-term PPI and atrophic gastritis.

Methane-hydrogen breathe test

To obtain accurate inspection results, patients must rinse the mouth before taking the substrate orally, then blew it into an airbag. After 30 minutes, the patient took 10 ml lactulose and repeated the above steps every 30 minutes until 8 airbags were collected. In the end, the exhaled air was detected by the Breath Tracker (Quintron, USA).

The following things need to be noted before testing. Patients should take the test on an empty stomach for more than 8 hours and only water throughout the examination. During the examination, intense exercise and smoking were forbidden.

SIBO diagnosis could be established with any one of the following conditions within 120 minutes of oral lactulose. ① Hydrogen concentration > 20 ppm; ② Increase in methane concentration > 12 ppm; ③ Increase in the sum of methane and hydrogen concentration > 15 ppm; ④ Double peak curve throughout the examination.

Treatment methods

All SIBO positive patients in the study group were divided into group A (n=22) and group B (n=28) according the different treatment. All patients received mesalazine (manufacturer: Shanghai Aidefa Pharmaceutical Co., Ltd., national medicine number: H20143164, specification: 0.5 g), 1 g/time, 4 times/d, 6 weeks. Group B received rifaximin (manufacturer: Shenyang Tonglian Pharmaceutical Co., Ltd., national medicine number: H20040052, specification: 0.2 g), 0.2 g/time, 4 times/d, 2 weeks plus.

Clinical efficacy

The clinical efficacy was evaluated by symptom plus microscopic examination or Mayo score alone (See Table 1). The total effective rate = (complete remission + markedly effective + effective)/all cases *100%.

Observation indexes

Venous samples were collected on empty stomach at early morning before and after treatment. Automatic biochemical analyzer 7100 (Hitachi, Japan) was adopted to measure CRP by immune scatter turbidity. ESR was detected by VES-matic Cube 200 ESR Analyzer (Sysmex, Japan). DAO and D-LA were detected by Enzyme-linked immunosorbent assay and kits were provided by Shanghai Tongwei Biotechnology Co., Ltd.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Complete remission</th>
<th>Markedly effective</th>
<th>Effective</th>
<th>Ineffective</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptom Disappearance</td>
<td>Sign. remission in most</td>
<td>Remission in most</td>
<td>No remission or exacerbation</td>
<td></td>
</tr>
<tr>
<td>Microscopic examination Decrease ≥ 95%</td>
<td>Normal</td>
<td>Decrease ≥ 70%</td>
<td>Decrease ≥ 30%</td>
<td>Decrease&lt;30%</td>
</tr>
<tr>
<td>Mayo score Decrease ≥ 95%</td>
<td>Normal</td>
<td>Remission in most</td>
<td>No remission</td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Evaluation criteria for clinical efficacy
Small intestinal bacterial overgrowth and evaluation of intestinal barrier

**Table 2. Comparison of the SIBO positive rate in the control group and study group [n (%)]**

<table>
<thead>
<tr>
<th>cases</th>
<th>Positive SIBO</th>
<th>Positive rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study group</td>
<td>89</td>
<td>50</td>
</tr>
<tr>
<td>Control group</td>
<td>40</td>
<td>10</td>
</tr>
<tr>
<td>$\chi^2$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P</td>
<td></td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

**Comparison of the serum DAO levels in groups A and B**

Before treatment, there was no statistical difference of DAO between the two groups ($P > 0.05$). After treatment, DAO of the two groups had decreased, lower in group B compared with group A (all $P<0.05$). See Figure 3.

**Comparison of serum D-LA levels before and after treatment**

Before treatment, there was no statistical difference of D-LA between the two groups ($P > 0.05$). After treatment, D-LA of the two groups had decreased, and group B had a lower level of D-LA ($P<0.05$). See Figure 4.

**Discussion**

UC usually exists in the colon and occasionally extends to the terminal ileum. Previous studies have demonstrated the importance of SIBO in patients with UC who present a higher positive rate in SIBO than healthy persons [15]. A large volume of published studies have found that the abnormal manifestation of the small intestine function in patients with UC and animal models is decreased in intestinal fluid, absorption of D-xylose, amino acids, and fat [16, 17]. There is a significant decrease in absorption of intestinal fluid and electrolytes in UC patients. Even in the remission period, the intestinal secretion capacity of patients with UC is different from a healthy person. Their proximal colonic mucosa is more sensitive to cAMP-dependent secretion but insensitive to Ca2+-dependent secretion. Genetic factors increase the intestinal permeability of patients with UC, even in remission. One study by Axel Dignass et al. [18] carried out a lactulose hydrogen breath test and a wireless dynamic capsule (a general gastrointestinal motility detection system that detects pressure, pH, and temperature) on patients, proving that the delay of orofecal transit time was prone to SIBO. IL-1β increase in the circular colic muscles may result in motility disorders of the colon in patients with UC due to hydrogen peroxide production.

It is now well established from a variety of studies that intestinal flora changes are one of the essential mechanisms inducing UC [19]. It has been confirmed that functions of normal intes-
Table 3. Comparison of the clinical efficacy of patients in groups A and B [n (%)]

<table>
<thead>
<tr>
<th>cases</th>
<th>Complete remission</th>
<th>Marked effective</th>
<th>effective</th>
<th>Ineffective</th>
<th>Total effective rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>group A</td>
<td>22</td>
<td>6 (27.27)</td>
<td>4 (18.18)</td>
<td>8 (36.36)</td>
<td>14 (63.64)</td>
</tr>
<tr>
<td>group B</td>
<td>28</td>
<td>16 (57.14)</td>
<td>5 (17.86)</td>
<td>2 (7.14)</td>
<td>26 (92.86)</td>
</tr>
</tbody>
</table>

χ² 6.5747
P 0.01

Figure 1. Comparison of ESR levels in groups A and B. Note: The X-axis indicates before and after treatment, and the Y-axis indicates the level of ESR (mm/h). The ESR levels of patients in group A before treatment were (40.02±10.75) mm/h while (20.3±7.3) mm/h after treatment. The ESR levels of patients in group B before treatment were (40.95±11.26) mm/h while (14.2±5.4) mm/h after treatment. ** means that a significant difference with P<0.01 and *** means that a significant difference with P<0.001.

Figure 2. Comparison of CRP levels in groups A and B. Note: The X-axis indicates before and after treatment, and the Y-axis indicates CRP level (mg/l). The CRP levels of patients in group A before treatment were (52.4±14.3) mg/l while (15.8±2.8) mg/l after treatment. The CRP levels of patients in group B before treatment were (51.7±13.5) mg/l while (12.0±2.2) mg/l after treatment. *** means that a significant difference with P<0.001.

Figure 3. Comparison of serum DAO levels in groups A and B. Note: The X-axis represents before and after treatment, and the Y-axis represents the serum DAO level (IU/ml). The serum DAO levels of patients in group A before treatment were (7.62±0.92) IU/ml while (5.63±0.22) IU/ml after treatment. The serum DAO levels of patients in group B before treatment were (7.58±0.88) IU/ml while (4.03±0.44) IU/ml after treatment. *** means that a significant difference with P<0.001.

Figure 4. Comparison of serum D-LA levels in groups A and B. Note: The X-axis represents before and after treatment, and the Y-axis represents the serum D-LA value (in mmol/L). The serum D-LA levels of patients in group A were (7.18±0.77) mmol/L before treatment while (5.48±0.63) mmol/L after treatment. The serum D-LA levels of patients in group B were (7.22±0.87) mmol/L before treatment while (3.22±0.38) mmol/L after treatment. *** means that a significant difference with P<0.001.
Small intestinal bacterial overgrowth and evaluation of intestinal barrier
	
Small intestinal flora are mostly manifested to inhibit the growth of pathogenic bacteria, strengthen the role of the epithelial barrier, and regulate inflammation through the Toll-like receptor pathway [20, 21]. Previous studies have shown a decrease in Firmicutes and Bacteroides in patients with UC but an increase in Proteobacteria and Actinomycetes. It has also been reported that the relationships between fecal microbiota and UC. Panagiotis Kourkoulis [22] et al. performed fecal microbiota transplantation on 35 UC patients, resulting in 31% ineffective and 69% remission. It has proved that a variety of probiotics maintained intestinal homeostasis by blocking the harm effects of bacteria, increased the integrity of the epithelial barrier, promoted innate immunity, and balanced inflammatory factors, thereby maintaining the remission of UC and preventing recurrence. Intestinal mucosal barrier function plays the role of the normal intestinal environment, and the dysfunction would lead to inflammatory bowel disease. D-LA, as the fermentation of intestinal bacteri, mainly exists in a highly active endoenzyme of the intestinal villus. When the intestinal mucosa function is damaged, D-LA and DAO enter the systemic circulation through blood, so D-LA and DAO was the important indexes to measure the intestinal barrier function.

In this study, patients with UC were treated with mesalazine and rifaximin. Rifaximin improves the clinical efficacy of mesalazine on UC after the eradication of SIBO. The group B presented greater total effective rate than group A. In accordance with the present results, previous studies [23, 24] have demonstrated that rifaximin helped alleviate the clinical symptoms of patients with UC, like the results in this study. In addition, mesalazine could decrease ESR and CRP levels. After treatment, there was a decrease in the ESR and CRP levels, and group B presented a significantly lower level (P<0.05), indicating eradication of SIBO beneficial to alleviate the condition. The adjustment of serum DAO and D-LA indexes facilitated the improvement of intestinal mucosal barrier function. Patients with UC presented abnormally high expression levels of serum D-LA and DAO, positively correlated with the disease severity [25]. The results showed a significant lower serum DAO and D-LA in group A (P<0.05), providing a stronger evidence. It is an observational study with a small number of participants and short follow-up. A randomized controlled study with a large sample is needed to confirm this conclusion further.

To sum up, patients with UC present a higher positive rate in SIBO in comparison with healthy persons. Mesalazine and rifaximin are applied to patients with mild to moderate UC, and their clinical efficacy has been significantly improved after the eradication of SIBO, indicating that this treatment works on patients with UC and significantly enhances the intestinal mucosal barrier function.

Disclosure of conflict of interest

None.

Address correspondence to: Jing Wang, Gastroenterology Department, The First Hospital of Hebei Medical University, 89 Donggang Rd, Yuhua Rd, Shijiazhuang, Hebei, China. Tel: +86-13633119599; E-mail: wangjingyida@163.com

References

[6] Bugda Gwilt K, Oliffe N, Hoffing RA and Miller GM. Trace amine associated receptor 1 (TAAR1) expression and modulation of inflam-
Small intestinal bacterial overgrowth and evaluation of intestinal barrier

matory cytokine production in mouse bone marrow-derived macrophages: a novel mechanism for inflammation in ulcerative colitis. Immunopharmacol Immunotoxicol 2019; 41: 577-585.


